Qilu Pharmaceutical Initiates Phase I Clinical Trial of QLS2313, a First-in-Class CD3/CD20/CD79b Trispecific Antibody for Relapsed/Refractory Hematologic Malignancies

▎Armstrong

On December 19, 2025, Qilu Pharmaceutical registered a Phase I clinical trial for QLS2313 Injection in the treatment of relapsed or refractory hematologic tumors on Clinicaltrials.gov.

This Phase I clinical trial plans to enroll 124 patients with relapsed/refractory hematologic malignancies and is expected to be completed in February 2028.

According to the enrollment information, QLS2313 is a globally first-in-class CD3/CD20/CD79b trispecific antibody.

Summary

B Cell Depleting in B-cell Lymphoma and Autoimmune Indications: The Competition for Iterative R&D is Particularly Intense